Tests AMG 127 for safety in healthy adults and adults with type 2 diabetes
Tests AMG 127 safety and tolerability in healthy adults and adults with type 2 diabetes.
Plain-language title generated from the registry record
Registry title: A Trial Evaluating AMG 127 in Healthy Participants and Participants With Type 2 Diabetes Mellitus
Key facts
- Where
- Aventura and Lake Forest, United StatesSee the 2 sites
- Phase
- Phase 1
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT07590193, who can take part
Where in United States
- Translational Clinical Research LLCAventura, United StatesTaking people
- Orange County Research CenterLake Forest, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Amgen
- Trial code
- NCT07590193
- Record updated
- 3 August 2026
- Original description
The main objective of this trial is to assess the safety and tolerability of AMG 127 as single dose and multiple doses in healthy participants and participants with type 2 diabetes mellitus (T2DM).Read full original descriptionShow less
A Phase 1 Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 127 in Healthy Participants and Participants With Type 2 Diabetes Mellitus
The main objective of this trial is to assess the safety and tolerability of AMG 127 as single dose and multiple doses in healthy participants and participants with type 2 diabetes mellitus (T2DM).
Inclusion: Participant must be 18-65 years of age; Participant must be overtly healthy; Participant must be 40-75 years of age; Confirmed diagnoses of T2DM.
Exclusion: History of hypotension, syncope, or orthostatic intolerance; History of hypotension, syncope, or orthostatic intolerance; Hemoglobin A1c (HbA1c) >10% within the last 3 months; Systolic blood pressure >140 millimeters of mercury (mmHg) or diastolic blood pressure >90 mmHg; Systolic blood pressure >160 mmHg or diastolic blood pressure >100 mmHg.